Results 171 to 180 of about 66,239 (358)

Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. [PDF]

, 2017
Nonvalvular atrial fibrillation (AF) is a risk factor for stroke in elderly patients. Although warfarin has been used to prevent AF-associated stroke for more than 50 years, non-vitamin K antagonist oral anticoagulants (NOACs) including dabigatran ...
Alexander, Ansell, Bathala, Camm, Connolly, Connolly, Eriksson, Giugliano, Goto, Granger, Harder, Heidbuchel, Hori, Hori, JCS Joint Working Group, Kimura, Matsushima, Mega, Mendell, Ogata, Ogawa, Oldgren, Oldgren, Patel, Sardar, Savelieva, Shen, Tanahashi, Tanigawa, Wong   +29 more
core   +1 more source

Adjustment for ‘Prescriber Type’ in Pharmacoepidemiological Analyses

Basic &Clinical Pharmacology &Toxicology, Volume 137, Issue 5, November 2025.
ABSTRACT The type of prescriber typically fulfils the criteria for confounding, as it is associated both with the exposure (e.g., prescriber types may differ in their choice of first‐line treatment) and with the outcome (as different types of prescribers often treat patients with different disease severity).
Saad Hanif Abbasi, Jesper Hallas, Peter Bjødstrup Jensen, Hassan Al‐Jasim, Anton Pottegård   +4 more
wiley   +1 more source

Treatment of Proximal Deep-Vein Thrombosis with the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients with Acute Symptomatic Deep-Vein Thrombosis) Study [PDF]

, 2008
G. Agnelli, A. Gallus, S.Z. Goldhaber
openalex   +1 more source

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

Clinical Pharmacology: Advances and Applications, 2014
Charles Frost,1 Yan Song,1 Yu Chen Barrett,1 Jessie Wang,2 Janice Pursley,3 Rebecca A Boyd,4 Frank LaCreta1 1Exploratory Clinical and Translational Research, 2Exploratory Development Global Biometric Sciences, 3Analytical and Bioanalytical Development ...
Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, LaCreta F   +6 more
doaj  

Safety profile of rivaroxaban in first-time users treated for venous thromboembolism in four European countries.

PLoS ONE
BackgroundThe European rivaroxaban post-authorization safety study evaluated bleeding risk among patients initiated on rivaroxaban or vitamin K antagonists for the treatment and secondary prevention of venous thromboembolism in routine clinical practice ...
Ana Ruigómez, Tania Schink, Annemarie Voss, Ron M C Herings, Elisabeth Smits, Karin Swart-Polinder, Yanina Balabanova, Gunnar Brobert, Kiliana Suzart-Woischnik, Luis Alberto García Rodríguez   +9 more
doaj   +1 more source

Efficacy of rivaroxaban for pulmonary embolism

Medicine, 2019
Abstract Background: Previous clinical trials have addressed that rivaroxaban is effective for the treatment of patients with pulmonary embolism (PE). This study will systematically assess its efficacy and safety for PE. Methods: We will carry out this study by searching
Ning Xu, Shi-min Xue, Juan Jia
openaire   +3 more sources

A Rare Cause of Neonatal Seizures—A Case Report

Journal of Paediatrics and Child Health, EarlyView.
Elysha Brennan, Dermot Wildes, Brian Cleary, Patrick Williams, Gabrielle Colleran, Michael A. Boyle   +5 more
wiley   +1 more source

Clinical associations and prognosis in Asian and European patients with symptom‐controlled atrial fibrillation: Insights from two prospective registries in Europe and Asia

European Journal of Clinical Investigation, Volume 55, Issue 11, November 2025.
Symptom‐controlled atrial fibrillation (AF), defined as asymptomatic or with mild symptoms according to the European Heart Rhythm Association (EHRA) score, was more common among Asians than in Europeans. In Asians, comorbidities of diabetes, hypertension, and prior ischemic stroke increase the likelihood of being scAF.
Wee Siong Teo, Manlin Zhao, Tommaso Bucci, Steven Ho Man Lam, Hongyu Liu, Yang Chen, Giuseppe Boriani, Hung‐Fat Tse, Tze‐Fan Chao, Gregory Y. H. Lip   +9 more
wiley   +1 more source

Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness

New England Journal of Medicine, 2018
Background Patients who are hospitalized for medical illness remain at risk for venous thromboembolism after discharge, but the role of extended thromboprophylaxis in the treatment of such patients is a subject of controversy. Methods In this randomized,
A. Spyropoulos, W. Ageno, G. Albers, G. Elliott, J. Halperin, W. Hiatt, G. Maynard, G. Steg, J. Weitz, E. Suh, T. Spiro, E. Barnathan, G. Raskob   +12 more
semanticscholar   +1 more source

Oral anticoagulation in patients with gastrointestinal bleeding and new‐onset atrial fibrillation: A population‐based registry‐linkage study

Journal of Internal Medicine, Volume 298, Issue 5, Page 450-463, November 2025.
Abstract Background Limited data exist on the prevalence of gastrointestinal bleeding (GIB) in patients with new‐onset atrial fibrillation (AF) and the impact of GIB on the initiation of oral anticoagulation (OAC) therapy. Methods A population‐based registry‐linkage study included all patients diagnosed with new‐onset AF in Finland during 2010–2018 who
Santeri Jolkkonen, Jukka Putaala, Konsta Teppo, Pirjo Mustonen, Jussi Jaakkola, Aapo Aro, Olli Halminen, Ossi Lehtonen, Jari Haukka, Miika Linna, Juha Hartikainen, K. E. Juhani Airaksinen, Mika Lehto   +12 more
wiley   +1 more source